We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Funding Agreed for Four Collaborative Research and Development Projects in Industrial Biotechnology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Funding Agreed for Four Collaborative Research and Development Projects in Industrial Biotechnology"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Four projects that will develop and commercialize innovative processes to generate high value chemicals through industrial biotechnology are to share £1.5 million of support funding from the Technology Strategy Board.

The research and development grant awards follow the conclusion of the second part of a funding call, Manufacturing High Value Chemicals through Industrial Biotechnology, run by the UK’s national innovation agency.

The projects will be led by Albany Molecular Research (UK) Ltd, Ensus Ltd, PML Applications Ltd and TerraVerdae Bioworks Ltd. The total cost of the projects, including contributions from the companies, will be in the region of £3 million.

The use of industrial biotechnology offers the potential to develop new, efficient and sustainable methods of obtaining a significant proportion of our energy, chemical and material needs.

Agricultural feedstocks, novel biocatalysts and bioreactor technologies have the potential to meet a number of challenges, such as replacing existing petrochemical-derived products like lubricants and plastics or creating active pharmaceutical ingredients through novel bio-transformations.

In February the Technology Strategy Board announced that it would invest £1 million in ten feasibility studies in industrial biotechnology.